🇺🇸 FDA
Pipeline program

Nivolumab

2023-503317-29-00

Phase 3 small_molecule active

Quick answer

Nivolumab for Metastatic Kidney Cancer is a Phase 3 program (small_molecule) at Rein Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Rein Therapeutics
Indication
Metastatic Kidney Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials